Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024.Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma (“MilliporeSigma ...

Financial Data and Key Metrics Changes - Revenue decreased by over 12% year-over-year, primarily due to market uncertainty, with a notable decline of $16.6 million in the oil and gas end market [10][11] - The company reported a GAAP net loss of $3.2 million or $0.10 per share, while the non-GAAP net loss was $0.01 per share for the first quarter [18] - Adjusted EBITDA decreased by $4.2 million to $12 million, marking the second highest first quarter adjusted EBITDA performance in the last five years [18] - Net cash provided by operating activities was $5.6 million, an increase of $5 million compared to the prior year [19] Business Line Data and Key Metrics Changes - The oil and gas end market experienced the largest revenue decline, particularly in the downstream sector, attributed to timing of turnarounds and project delays [10][11] - Aerospace and defense revenue declined by $1.7 million due to macroeconomic uncertainties and supply chain disruptions [11][12] - The Data Solutions Group, particularly the PCMS offering, saw a revenue growth of 6% compared to the prior year [13] Market Data and Key Metrics Changes - The international segment revenue increased by nearly 4% in local currency, although this was offset by adverse foreign exchange translation [16] - The company noted a reduction in customer spending and project pushouts in upstream and midstream sub-industries due to market uncertainties [11] Company Strategy and Development Direction - The company is focusing on three key initiatives: leadership talent evaluation, recalibration of cost base, and developing growth strategies across all businesses [6][7] - Mistras is emphasizing accelerated expansion in core end markets like oil and gas and aerospace and defense, with a focus on integrated solutions leveraging data analytics [7][9] - The launch of the Mistras Data Solution brand consolidates data-centric services and technologies, aiming to enhance operations for asset-intensive end markets [10] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for the remainder of the year despite a slower start in key markets, with expectations of recovering revenue in the oil and gas sector [11][12] - The company is closely monitoring potential industry headwinds caused by global market uncertainties and tariffs [12][23] - Management anticipates that adjusted EBITDA for 2025 will at least meet or exceed the levels achieved in 2024 [24] Other Important Information - The company is not providing full-year guidance for fiscal 2025 due to unprecedented market uncertainty [23] - The effective tax rate for the first quarter was a tax benefit of 26.9%, with an anticipated rate of approximately 25% for the full year [20] Q&A Session Summary Question: Changes in the operating environment compared to three months ago - Management noted unprecedented uncertainty affecting project delays and customer evaluations regarding tariffs [33][34] Question: Impact of tariffs on business and project delays - The direct impact of tariffs on Mistras is minimal, but customers are pausing or delaying spending due to economic conditions [42] Question: Pricing initiatives and customer discussions - The company is maintaining commercial discipline and reviewing contract economics to ensure fair ROI for services [37][38] Question: Outlook on midstream and downstream markets - Revenue reduction in midstream is attributed to budget restrictions and regulatory drivers, with expectations of demand recovery later in the year [53] Question: Expectations for revenue and EBITDA - Management indicated that adjusted EBITDA is expected to be similar to last year, suggesting that revenue may not be significantly lower than the previous year [55][56]

Core Viewpoint - Advantest Corporation has introduced SiConic Test Engineering (TE), enhancing the SiConic ecosystem to empower test engineers throughout the development lifecycle, facilitating earlier validation and debugging without utilizing ATE systems [1][6]. Group 1: Product Features - SiConic TE allows test engineers to validate and debug design verification (DV) and design for test (DFT) content in a unified environment, connecting flexibly to standard evaluation boards via interfaces like USB and PCIe [2][3]. - The integration of SiConic TE with SiConic Link hardware and SmarTest 8 software enhances throughput and trace capabilities during test execution, promoting collaboration among silicon validation (SV), DV, and TE teams [4][5]. - SiConic TE optimizes engineering resources by offloading bring-up and debug tasks from ATE to the bench, improving correlation between bench, ATE, and SLT systems [5]. Group 2: Industry Collaboration - Advantest developed SiConic TE in collaboration with leading customers and EDA partners to ensure seamless integration into existing design and validation workflows [7]. - The partnership with Siemens EDA focuses on improving time-to-market and productivity through joint development of DFT technologies [8]. - Collaboration with Synopsys aims to enhance verification approaches, enabling users to validate high-speed interfaces and perform functional testing through the combined capabilities of Advantest's SiConic platform and Synopsys' solutions [8]. Group 3: Market Impact - SiConic TE is expected to improve productivity at the R&D level, allowing concurrent sign-off and test engineering processes, which can accelerate SoC design ramp-up and reduce time-to-market [6]. - Advantest's commitment to addressing emerging testing challenges positions the company as a leader in the semiconductor test equipment market, catering to applications such as 5G, IoT, and AI [10].

Veracyte (VCYT) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 and thank you for standing by. Welcome to the Veracyte First Quarter twenty twenty five Financial Results Webcast. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Sheila Gorman, Senior Director, Investor Relations. P ...

veracyte. Q1 2025 Earnings Presentation May 7, 2025 2 © 2025 Veracvte. Inc. All rights reserved. © 2025 Veracyte, Inc. All rights reserved. 3 Forward-looking statements and non-GAAP information This presentation contains forward-kodoling, statements, including, but not lintied to our plans, dbjectives, and expectives, and expectabions (financial and othernise), i 2025 and 2020 fina vial and operating results our assumptions for future reveave royst: plans and friming of the release of version 2.0 cour' leng ...

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webina ...

Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Todd Spencer - Vice President, Investor RelationsJames Foster - Chairman, President and CEOFlavia Pease - Corporate Executive VP & CFOElizabeth Anderson - Senior Managing DirectorDave Windley - Managing DirectorMichael Ryskin - Managing DirectorKyle Crews - Equity Research AssociatePatrick Donnelly - Managing DirectorCasey Woodring - Vice President - Equity ResearchCharles Rhyee - Managing Dire ...

Charles River Laboratories 1Q 2025 Results May 7, 2025 © 2025 Charles River Laboratories International, Inc. Safe Harbor Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that p ...

Personalis (PSNL) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Company Participants Caroline Corner - Investor RelationsChristopher Hall - CEO and PresidentAaron Tachibana - CFO & COORichard Chen - Executive VP of R&D and Chief Medical OfficerVidyun Bais - Equity Research - Vice PresidentYuko Oku - Equity Research Associate Conference Call Participants Thomas Flaten - Senior Research AnalystWilliam Bonello - Senior Research AnalystJoseph Stringer - Senior AnalystDaniel Brennan - Senior Equity Research Ana ...

Personalis (PSNL) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Speaker0 Greetings. Welcome to the Personalis First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I would now like to turn the call over to Caroline Corner. Please go ahead. Speaker1 Thank you, operator. Welcome to Personalis' first quarter twenty twenty five earnings ...